NCT05142228View on ClinicalTrials.gov

Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 31, 2022

Primary Completion Date

October 27, 2022

Study Completion Date

October 27, 2022

Conditions
Trigeminal Neuropathy
Interventions
DRUG

Erenumab-Aooe

Administered once every 4weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.

OTHER

Placebo

Administered once every 4weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.

Trial Locations (1)

21201

University of Maryland, School of Dentistry, Brotman Facial Pain Clinic, Baltimore

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

University of Maryland, Baltimore

OTHER

NCT05142228 - Erenumab-aooe for the Management of Trigeminal Neuropathic Pain. | Biotech Hunter | Biotech Hunter